In vitro and in vivo characterization of TC-1827, a novel brain α4β2 nicotinic receptor agonist with pro-cognitive activity

Drug Development Research

Volumn 62, Issue 1, 2004, Pages 26-40

  Bohme, Georg Andrees ^a   Letchworth, Sharon R ^b   Piot Grosjean, Odile ^a   Gatto, Gregory J ^b   Obinu, Marie Carmen ^a   Caldwell, William S ^b   Laville, Michel ^a   Brunel, Pascale ^a   Pellerin, Rachel ^a   Leconte, Jean Pierre ^a   Genevois Borella, Arielle ^a   Dubedat, Pierre ^a   Mazadier, Martine ^a   Pradier, Laurent ^a   Bencherif, Merouane ^b   Benavides, Jesus ^a  

^a SANOFI   (France)

^b TARGACEPT INC   (United States)

Author keywords

Acetylcholine receptors; Alzheimer's disease; Ion flux; Learning and memory; Long term potentiation; Neurotransmitter release

Indexed keywords

ACETYLCHOLINE; ALPHA4 BETA2 NICOTINIC RECEPTOR; CHOLINERGIC RECEPTOR; CYSTINE; DOPAMINE; NEUROTRANSMITTER; NICOTINIC AGENT; NICOTINIC RECEPTOR; SCOPOLAMINE; TC 1827; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BLOOD PRESSURE; BRAIN CORTEX; CARDIOVASCULAR FUNCTION; COGNITION; COGNITIVE DEFECT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOG; DOPAMINE RELEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; FIRST PASS EFFECT; HEART RATE; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; LATENT PERIOD; LEARNING; LONG TERM POTENTIATION; MALE; MEMORY; MICRODIALYSIS; MOUSE; NERVE CELL PLASTICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; RAT; SYNAPTOSOME; TETANIC SPASM;

EID: 7644230110     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10352     Document Type: Article

References (42)

1. Bencherif M, Lovette ME, Fowler KW, Arrington S, Reeves L, Caldwell WS, Lipiello PM. 1996. RJR-2403: a nicotinic agonist with CNS selectivity I. In vitro characterization. J Pharmacol Exp Ther 279:1413-1421.
2. Bencherif M, Schmitt JD, Bhatti BS, Crooks P, Caldwell WS, Lovette ME, Fowler K, Reeves L, Lipiello PM. 1998. The heterocyclic substituted pyridine derivative (±)-2-(-3-pyridinyl)-1-azabicyclo[2.2.2]octane (RJR-2429): a selective ligand at nicotinic acetylcholine receptors. J Pharmacol Exp Ther 284:886-894.
3. Bliss TVP, Collingridge GL. 1993. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361:31-39.
4. Brenner DE, Kukull WA, Van Belle G, Bowen JD, McCormick WC, Teri L, Larson EB. 1993. Relationship between cigarette smoking and Alzheimer's disease in a population-based case-control study. Neurology 43:293-300.
5. Brioni JD, Arneric SP. 1993. Nicotinic recepfors facilitate retention of avoidance training: participation of dopaminergic mechanisms. Behav Neural Biol 59:57-62.
6. Buccafusco JJ, Terry AV. 2002. Nicotine and cognition in young and aged nonhuman primates. In: Levin ED, editor. Nicotinic receptors in the nervous system. Boca Raton: CRC Press, p 179-197.
7. Dani JA. 2001. Nicotine mechanisms in Alzheimer's disease: Overview of nicotinic receptors and their roles in the central nervous system. Biol Psychiatry 49:166-174.
8. 3H]- methyllycaconitine: a new radioligand for labelling α7-type neuronal nicotinic acetylcholine receptors. Neuropharmacol 38:679-690.
9. Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Radeck RJ, Raszkiewicz JL, Kang CH, Kim DJB, Giardina WJ, Wasicak JT, Garvey DS, Williams M, Arneric SP. 1994. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)Isoxazqle (ABT-418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities; II. In vivo characterization. J Pharmacol Exp Ther 270:319-328.
10. Dodart JC, Mathis C, Ungerer A, 1997. Scopolamine-induced deficits in a two-trial object recognition task in mice, Neuroreport 8:1173-1178.
11. Dunckley T, Lukas RJ. 2003. Nicotine modulates the expression of a diverse set of genes in the neuronal SH-SY5Y cell line. J Biol Chem 278:15633-15640.
12. Dringenberg HC. 2000. Alzheimer's disease: More than a 'cholinergic disorder': evidence that cholinergic-monoaminergic interactions contribute to EEG slowing and dementia. Behav Brain Res 115:235-249.
13. 3H]cytisine. Life Sci 54:1883-1890.
14. Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ. 1992. A subtype of nicotinic cholinergic receptors in the rat brain is composed of α4 and β2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol 41:31-37.
15. Francis PT, Palmer AM, Snape M, Wilcock GK. 1999. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 66:137-147.
16. French SJ, Humby T, Horner CH, Sofroniew MV, Rattray M. 1999. Hippocampal neurotrophin and trk receptor mRNA levels are altered by local administration of nicotine, carbachol and pilocarpine. Mol Brain Res 67:124-136.
17. Holladay MW, Dart MJ, Lynch JK. 1997. Neuronal nicotinic receptors as targets for drug discovery. J Med Chem 40:4169-4194.
18. 3H]- nicotine to a single class of high affinity sites in rat brain membranes. Mol Pharmacol 29:448-454.
19. Lippiello PM, Bencherif M, Gray JA, Peters S, Grigoryan G, Hodges H, Collins AC. 1996. RJR-2403: a nicotinic agonist with CNS selectivity II. In vivo characterization. J Pharmacol Exp Ther 279:1422-1429.
20. Lee PN. 1994. Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology 13:131-144.
21. Levin ED, Rezvani AH. 2002. Nicotinic involvement in cognitive function of rats. In: Levin ED, editor. Nicotinic receptors in the nervous system. Boca Raton, CRC Press, p 167-178.
22. Lloyd GK, Williams, M. 2000. Neural nicotinic acetylcholine receptors as novel drug targets. J Pharmacol Exp Ther 292:461-467.
23. Lukas RJ Cullen MJ. 1988. An isotopic rubidium efflux assay for the functional characterization of nicotinic acetylcholine receptors on clonal cell lines. Anal Biochem 175:212-218.
24. Lukas RJ, Changeux JP, Le Novère N, Albuquerque EX, Balfour DJK, Berg DK, Bertrand D, Chiappinelli VA, Clarke PBS, Collins AC, Dani JA, Grady SR, Kellar KJ, Lindstrom JM, Marks MJ, Quik M, Taylor PW, Wonnacott S. 1999. International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev 51:397-401.
25. Matsuyama S, Matsumoto A, Enomoto T, Nishizaki T. 2000. Activation of nicotinic acetylcholine receptors induces long-term potentiation in vivo in the intact mouse dentate gyms. Eur J Neurosci 12:3741-3747.
26. McGehee DS, Role LW. 1995. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Ann Rev Physiol 57:521-546.
27. Newhpuse PA, Sunderland T, Tariot PN, Blumhardt CL, Weingartner H, Mellow A, Murphy DL. 1988. Intravenous nicotine in Alzheimer's disease a pilot study. Psychopharmacology 95:171-175.
28. Newhouse PA, Potter A, Corwin J, Lenox R. 1994. Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology 10:93-107.
29. Obinu MC, Reibaud M, Miquet JM, Pasquet M, Rooney T. 2002. Brain-selective stimulation of nicotinic receptors by TC-1734 enhances ACh-transmission from frontoparietal cortex and memory in rodents. Prog Neuro-psychopharmacol Biol Psychiatry 26:913-918.
30. Palmer AM, Gershon S. 1990. Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic? FASEB J. 4:2745-2752.
31. Palmer T. 1996. Agents acting at the neuromuscular junction and autonomic ganglia. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilnian A, editors. The pharmacological basis of therapeutics, 9th ed. New York, McGraw-Hill. p 177-197.
32. Paterson D, Nordberg A. 2000. Neuronal nicotinic receptors in the human brain. Prog Neurobiol 61:75-111.
33. Picciotto MR, Zoli M, Léna C, Bessis A, Lallemand Y, Le Novère N, Vincent P, Merlo Pich E, Brûlet P, Changera JP. 1995. Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature 374:65-67.
34. Potter A, Corwin J, Lang J, Piasecki M, Lenox R, Newhouse PA. 1999. Acute effect of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacology 142:334-342.
35. Sanberg PR, Silver AA, Shytle RD, Philipp MK, Cahill DW, Fogelson HM, McConville BJ. 1997. Nicotine for the treatment of Tourettes's Syndrome. Pharmacol Ther 74:21-25.
36. Sahakian B, Jones G, Levy R, Gray J, Warburton D. 1989. The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry 154:797-800.
37. 2* subtype in the modulation of dopamine release from rat striatal synaptosomes. J Neurosci 20:2783-2791.
38. Staubli U, Rogers G, Lynch G. 1994. Facilitation of glutamate receptors enhances memory. Proc Natl Acad Sci USA 91:777-781.
39. Summers KL, Lipiello P, Giacobini E. 1996. A microdialysis study of the effects of the nicotinic agonist RJR-2403 on cortical release of acetylcholine and biogenic amines. Neurochem Res 21:1181-1186.
40. Sun B, Sterling CR, Tank AW. 2003. Chronic nicotine treatment leads to sustained stimulation of tyrosine hydroxylase gene transcription rate in rat adrenal medulla. J Pharmacol Exp Ther 304:575-588.
41. Wilson AL, Kangley LK, Monley J, Bauer T, Rottunda S, McFalls E, Kovera C, McCarten JR. 1995. Nicotine patches in Alzheimer's disease: pilot study on learning, memory and safety. Pharmacol Biochem Behav 51:509-514.
42. Wonnacott S. 1997. Presynaptic nicotinic Ach receptors. Trends Neurosci 20:92-98.